Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
linear decrease » linear increase (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
linear decrease » linear increase (Expand Search)
-
2341
-
2342
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2343
-
2344
-
2345
-
2346
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2347
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2348
-
2349
-
2350
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2351
-
2352
-
2353
-
2354
-
2355
-
2356
-
2357
-
2358
Molecular docking showed that ABT-199 can fit into active site of ALK<sup>Mutant</sup>.
Published 2025Subjects: -
2359
-
2360